Cytokinetics (NASDAQ:CYTK) reported positive interim results from the first cohort of its Phase 2 REDWOOD-HCM clinical trial evaluating CK-274 for the treatment of hypertrophic cardiomyopathy.
In the first cohort, 21 patients were randomized to receive escalating doses of CK-274, a cardiac myosin inhibitor, or placebo. Data from the first cohort demonstrated that patients experienced substantial reductions in the average resting left ventricular outflow tract (LVOT) gradient.
In addition, LVOT gradient reductions were observed after patients performed the Valsalva maneuver, which uses a particular breathing technique to increase pressure in the chest.
Based on these results, REDWOOD-HCM’s steering and data monitoring committees have recommended that the trial proceed to cohort 2, which is now open for enrollment.
“We are encouraged that clinically relevant reductions in the LVOT gradient were achieved within four-to-six weeks in the majority of patients of cohort 1 in this interim analysis,” Fady Malik, M.D., Cytokinetics’ EVP of research and development, said in a statement.
“We hope to rapidly enroll cohort 2 with the goal of sharing results from REDWOOD-HCM in the middle of 2021 as may support progression of CK-274 to a planned Phase 3 by the end of next year.”
